From Wikipedia, the free encyclopedia
This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their
pharmaceutical drug candidates. Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematic
chemical names , and for which the effort to generate nonproprietary names may not be warranted, see article on
drug nomenclature . Instead, these compounds are usually given a number for internal reference at the company. To distinguish the numbered compounds from different companies (or academic laboratories), each compound number is prefixed with a letter code indicating the company that developed the compound, that claims
intellectual property on that compound etc. The letter code is conceived by companies themselves who should be interested in creating a unique code. Three main methods are found for prefixing the numeric identifier – with a space (gap),
[1] with nothing (concatenated),
[2]
[3] and with a dash (or hyphen).
[4]
For example, ABT-199 is a compound developed at
Abbott Laboratories , and this name has been used in early publications of research results. Later the compound was assigned the
international nonproprietary name (INN)
venetoclax . Similarly, other compounds may be given a
USAN or
BAN for example. Finally, the compound may be given a
trade name for example for marketing purposes.
A long list of code designations with corresponding
trade names can be found in Appendix IV of the USP Dictionary, see article on
drug nomenclature .
Note that this convention of composing compound identifiers from a company identifier followed by a number is not always followed. For example, the letter code may reflect a therapeutic/disease area or an internal project name. A randomly picked example is SC for spinal cord injury.
[5]
A to F
ARQ –
ArQule
ARRY
Array BioPharma
ASP –
Astellas Pharma
[9]
AT –
Arecor Therapeutics
[10]
ATB -
Antibe Therapeutics
ATL –
Antisense Therapeutics Limited, Australia
AVXS –
AveXis , in May 2018 acquired by Novartis
AY –
Ayerst , later Wyeth-Ayerst, ultimately acquired by Pfizer
AZD –
AstraZeneca
BAN –
BioArctic Neuroscience AB, Sweden
BAY –
Bayer AG
BB –
Bluebird Bio
BCX –
Laboratoires Biocodex
BI -
Boehringer Ingelheim
BIIB –
Biogen
BMS –
Bristol-Myers Squibb
BMY – Bristol-Myers Co., merging in 1989 into Bristol-Myers Squibb
BRL – Beecham Research Labs, merged with SmithKline into SmithKline Beecham which merged into GlaxoSmithKline
BTC –
The Boots Company plc
C –
Laboratoires Cassenne
CAM –
Cambridge Antibody Technology , acquired by AstraZeneca
CAS –
Cassella Farbwerke Mainkur Aktiengesellschaft , later Hoechst, later Sanofi
CAT –
Cannasat Therapeutics Inc., renamed 2010
Cynapsus Therapeutics
CAT –
Cambridge Antibody Technology , acquired by
AstraZeneca
CC –
Celgene
CE –
Pfizer
CGS –
Ciba Geigy
CP – Pfizer. CP refers to
C. P. Pharmaceuticals , a subsidiary of Pfizer
[11]
CSL –
CSL Limited , an Australian biopharmaceutical company
CVX –
CovX , acquired by
Pfizer in 2008
CYT –
Cytopia of Australia, acquired by
YM Biosciences , subsequently by
Gilead Sciences
[12]
D –
Draco division of
Astra AB , now
AstraZeneca
DMP – DuPont Merck Pharmaceuticals, a joint venture between
DuPont and
Merck ; became
DuPont Pharmaceuticals in 1998
DPC –
DuPont Pharmaceuticals , acquired by
Bristol-Myers Squibb in 2001
DS -
Daiichi Sankyo
DX –
Dyax
EAG –
Eagle Pharmacy , a United States pharmaceutical compounding company
[13]
EIDD –
Emory Institute for Drug Development
EMD –
Merck KGaA (E. Merck), Darmstadt, Germany (refers to laboratory founder Emanuel Merck in
Darmstadt )
ETC –
Esperion Therapeutics , acquired by Pfizer in 2003, independent again since 2008
F –
Forest Labs , acquired by
Actavis
FCE –
Farmitalia-Carlo Erba , later
Pharmacia AB, later Pharmacia & Upjohn, acquired by
Pfizer
FF –
Fujifilm
FG –
FibroGen
FK –
Fermentek
FPI –
Fusion Pharmaceuticals
FS –
F-star
G to L
G – J. R. Geigy AG, ultimately merged into
Novartis
G –
Genta Inc.
GDC –
Genentech Likely Genentech Development Candidate
[14]
[15]
GEH –
GE Healthcare
GNE –
Genentech internal reference number, company pipeline uses GDC- prefixes
[14]
[16]
GP – Geigy, merged with CIBA in 1971 to become
Ciba-Geigy , now
Novartis
GR –
GlaxoSmithKline
GS –
Gilead Sciences
GS –
Gesynta Pharma
[17]
GSK –
GlaxoSmithKline
H – Hässle division of
Astra AB , now
AstraZeneca
HCV –
ViroPharma
HOE –
Hoechst AG
ICI –
Imperial Chemical Industries , acquired by
AkzoNobel and merged into
Zeneca Group by the merger of the pharmaceutical operations. Now part of
AstraZeneca
IDN –
Idun Pharmaceuticals , acquired by
Pfizer
ILY –
Ilypsa , acquired by
Amgen in 2007
INNO –
CytRx
ION –
Ionis
IPI –
Infinity Pharmaceuticals , Inc
ISIS –
Isis Pharmaceuticals (renamed Ionis Pharmaceuticals in 2015)
JNJ –
Johnson & Johnson
KOS –
Kosan Biosciences
KPT –
Karyopharm Therapeutics
KU –
KuDOS Pharmaceuticals
KW –
Kyowa Hakko
L –
Labaz Group , acquired by
Elf Aquitaine in 1973 to form
Sanofi
LU –
Lundbeck
LY –
Eli Lilly
M to S
MBX -
MBX Biosciences
[18]
MCN –
McNeil Laboratories , now part of Johnson & Johnson
MDCO –
The Medicines Company
MDL –
Merrell Dow Pharmaceuticals
MEDI –
MedImmune , acquired by
AstraZeneca
[19]
MEM –
Memory Pharmaceuticals
MGX –
Victory Pharma
MK –
Merck & Co. (Merck Sharp & Dohme)
MLN –
Millennium Pharmaceuticals
MT –
Micromet , acquired by
Amgen in 2012
NBI –
Neurocrine Biosciences
[20]
NC –
Nycomed
NC –
Nippon Chemiphar
NCX –
NicOx
NG –
Neurogen Corp.
NI –
Neurimmune
NKTR –
Nektar Therapeutics
NVS –
Novartis
OGX –
OncoGenex
OPC –
Otsuka Pharmaceutical Co.
OSI –
OSI Pharmaceuticals
PD –
Parke-Davis , now
Pfizer
PF –
Pfizer
PHA –
Pharmacia , now
Pfizer
PNU –
Pharmacia & Upjohn , now
Pfizer
PT –
Pearl Therapeutics , now part of
AstraZeneca
PTI –
Proteostasis Therapeutics Inc
R –
Janssen Pharmaceutica , now part of
Johnson & Johnson (Janssen began as Belgian and Dutch distributor for products of
Gedeon Richter Plc. )
RDEA –
Ardea Biosciences acquired by
AstraZeneca
RDX –
Ardelyx
RXC -
Redx Pharma
REGN –
Regeneron Pharmaceuticals
[2]
RLY –
Relypsa
RMI –
Richardson-Merrell
RO –
Hoffmann–La Roche
RP –
ReceptorPharma
RPC – Receptos, now
Celgene
RTI–
Research Triangle Institute (mostly restricted to various
phenyltropanes )
RU –
Roussel Uclaf
RWJ –
R.W. Johnson Pharmaceutical Research , now part of Johnson & Johnson
SAGE –
Sage Therapeutics
SAN –
Sandoz Pharmaceuticals , now
Novartis
SB –
SmithKline Beecham , now
GlaxoSmithKline
SC –
G.D. Searle , now
Pfizer
SCH –
Schering Corp., later
Schering-Plough
SKF –
Smith, Kline & French , later merged into
GlaxoSmithKline
SLV –
Solvay
SNS –
Sunesis Pharmaceuticals
[21]
SNS –
Sensei Biotherapeutics
[22]
SPD –
Shire
SPI –
Spectrum Pharmaceuticals
SU –
CIBA Pharmaceutical Company (the Summit, NJ site)
SU –
SUGEN , now
Pfizer
T to Z
TAK –
Takeda
TC –
Targacept Inc.
TD -
Theravance Biopharma
[23]
TERN –
Terns Pharma
[24]
TG –
Tragara Pharmaceuticals Inc., San Diego, CA
TH –
Threshold Pharmaceuticals Inc.
[25]
TKS –
Thiakis Limited , a UK biotech company (acquired by
Wyeth in 2008).
[26]
TM –
TransMolecular
[27]
TMC –
Tibotec
TNP – Takeda Neosplastic Product, from
Takeda Pharmaceutical Company
TNX –
Tanox , now Genentech/Roche
TOS –
Totus Medicines
[28]
[29]
[30]
TS –
Taisho Pharmaceutical Co. , a Japanese Pharmaceutical Company
[31]
U –
Upjohn (merged with
Pharmacia 1995)
UCL –
University College London
[32]
UK –
Pfizer Sandwich, UK
USL –
Upsher-Smith Laboratories
UTE -
University of Utah
VET –
Veterna S.r.l.
VX –
Vertex Pharmaceuticals
WAY –
Wyeth (Wyeth-Ayerst, acquired by
Pfizer in 2009)
WY –
Wyeth (merged with Ayerst 1987)
XL –
Exelixis
[3]
XTL –
XTL Biopharmaceuticals
XU –
Sandoz Pharmaceuticals , now
Novartis
ZD –
Zeneca , now
AstraZeneca
ZS –
ZS Pharma , acquired by
AstraZeneca
References
^
"ArQule clinical pipeline" . Retrieved 2016-09-16 .
^
a
b
"Regeneron PCSK9 Antibody REGN727" . Archived from
the original on 2012-04-16. Retrieved 2012-04-17 .
^
a
b
"Exelixis HSP90 inhibitor XL888" . Archived from
the original on 2016-09-18. Retrieved 2016-09-16 .
^
a
b
"AbbVie pipeline, using ABBV- as prefix" . Retrieved 2016-09-16 .
^
"SC0806 clinical trial" . Retrieved 2018-07-26 .
^
a
b
"AbbVie spun out of Abbott" . 30 December 2012. Retrieved 2016-09-15 .
^
"ADL5747" . Retrieved 2008-03-19 . [
dead link ]
^
"Amgen goes 6-for-6 in Phase III" . 17 March 2014. Retrieved 2014-11-25 .
^
"Overview of R&D Pipeline" (PDF) . Retrieved 2018-12-30 .
^
"Our Portfolio" . Arecor Therapeutics . Retrieved 12 June 2023 .
^ Drawbaugh, Tom Bergin (16 November 2015).
"How Pfizer has shifted U.S. profits overseas for years" . Reuters . Retrieved 2019-11-06 .
^
"Edison outlook report on YM Biosciences" (PDF) . Retrieved 2016-09-19 .
^
"Eagle Pharmacy – Pharmaceutical Compounding" . Retrieved 2016-04-26 .
^
a
b
"Genentech Pipeline" . Retrieved 2016-09-29 .
^ Crawford, Terry D.; Romero, F. Anthony; Lai, Kwong Wah; Tsui, Vickie; Taylor, Alexander M.; De Leon Boenig, Gladys; Noland, Cameron L.; Murray, Jeremy; Ly, Justin; Choo, Edna F.; Hunsaker, Thomas L.; Chan, Emily W.; Merchant, Mark; Kharbanda, Samir; Gascoigne, Karen E.; Kaufman, Susan; Beresini, Maureen H.; Liao, Jiangpeng; Liu, Wenfeng; Chen, Kevin X.; Chen, Zhongguo; Conery, Andrew R.; Côté, Alexandre; Jayaram, Hariharan; Jiang, Ying; Kiefer, James R.; Kleinheinz, Tracy; Li, Yingjie; Maher, Jonathan; et al. (2016). "GDC-0152". Journal of Medicinal Chemistry . 59 (23): 10549–10563.
doi :
10.1021/acs.jmedchem.6b01022 .
PMID
27682507 .
^ Crawford, Terry D.; Romero, F. Anthony; Lai, Kwong Wah; Tsui, Vickie; Taylor, Alexander M.; De Leon Boenig, Gladys; Noland, Cameron L.; Murray, Jeremy; Ly, Justin; Choo, Edna F.; Hunsaker, Thomas L.; Chan, Emily W.; Merchant, Mark; Kharbanda, Samir; Gascoigne, Karen E.; Kaufman, Susan; Beresini, Maureen H.; Liao, Jiangpeng; Liu, Wenfeng; Chen, Kevin X.; Chen, Zhongguo; Conery, Andrew R.; Côté, Alexandre; Jayaram, Hariharan; Jiang, Ying; Kiefer, James R.; Kleinheinz, Tracy; Li, Yingjie; Maher, Jonathan; et al. (2016). "GNE-272". Journal of Medicinal Chemistry . 59 (23): 10549–10563.
doi :
10.1021/acs.jmedchem.6b01022 .
PMID
27682507 .
^
"First patients dosed in phase II study of GS-248 in systemic sclerosis" . Bioworld Science . Clarivate Analytics. Retrieved 27 January 2021 .
^
"MBX 2109" . Retrieved 2024-02-12 .
^
"Pipeline – AstraZeneca" . Retrieved 2018-12-30 .
^
"Neurocrine Vmat2 inhibitor NBI-98854" . Archived from
the original on 2015-01-30. Retrieved 2016-09-13 .
^
"Sunesis BTK inhibitor SNS-062" . Retrieved 2016-09-15 .
^
"Sensei biotherapeutics anti VISTA" (Press release). October 2021. Retrieved 2021-11-29 .
^
"Theravance Biopharma Pipeline" . Theravance pipeline background image . Retrieved 2024-02-12 .
^
"Pipeline" . Terns Pharma pipeline . Retrieved 27 January 2021 .
^
"TH-302 clinical trial" . Retrieved 2013-07-23 .
^
"MM&M News" . 2008-12-18. Retrieved 2009-02-16 .
^
"TransMolecular Product Pipeline" . Archived from
the original on 2007-07-29. Retrieved 2007-11-18 .
^
"Pipeline" . Totus Medicines Pipeline . Retrieved 25 August 2023 .
^
"TOS-358 Clinical Trial" . Retrieved 25 August 2023 .
^
"Preclinical characterization of TOS-358, a potent and selective covalent inhibitor of wild-type and mutant PI3Kα with superior anticancer activity" . Retrieved 25 August 2023 .
^
"Taisho Press Release" . Retrieved 2008-01-07 .
^
"UCL1684 at pubchem.gov" . Retrieved 2018-03-24 .